{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-070108","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2023-08-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.156679+00:00","generated_at":"2026-06-11T04:45:33.112303+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Adial Pharmaceuticals regains Nasdaq compliance on bid price and equity requirements","bullets":["Received Nasdaq notice on Aug 21, 2023, confirming minimum bid price compliance (Rule 5550(a)(2)) after 10 consecutive days at $1.00+.","Received second notice on Aug 22, 2023, confirming regained compliance with stockholders' equity minimum of $2.5 million.","All outstanding Nasdaq listing deficiencies are now resolved; the matters are closed."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-070108","json":"https://secwatch.observer/filing/0001213900-23-070108.json","markdown":"https://secwatch.observer/filing/0001213900-23-070108.md","text":"https://secwatch.observer/filing/0001213900-23-070108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023070108/0001213900-23-070108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023070108/ea184064-8k_adialpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T04:45:33.112303+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0505ce34f8ac7928ec6da0115a674b41278408d0","claim":"ADIAL PHARMACEUTICALS, INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2), 5550(b)(1)).","evidence_excerpt":"August 7, 2023 to August 18, 2023, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Staff has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and that the matter is now closed. On August 22, 2023, the Company also received a notice from the Staff that it now complies with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders’ equity of at least $2,500,000 and that the matter is now closed. On August 23, 2023, the Company issued a press release announcing that t","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023070108/0001213900-23-070108-index.htm","confidence":0.82,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"compliance regained"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}